According to filings with the U.S. Securities and Exchange Commission, CeleCor Therapeutics is raising up to $15 Million in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About CeleCor Therapeutics
CeleCor Therapeutics is a biotechnology company focused on improving the treatment of ST-segment elevation myocardial infarctions (STEMI heart attacks) at the first point of medical contact. The company is developing zalunfiban (also referred to as Disaggpro), an investigational next-generation GPIIb/IIIa platelet inhibitor specifically designed for pre-hospital treatment of STEMI and administered as a single subcutaneous injection. Its core mission is to provide prompt, potent, and predictable platelet inhibition in patients experiencing a serious heart attack before they reach the hospital, with the goal of getting them there with open coronary arteries and better-preserved heart muscle. CeleCor is running the CeleBrate trial, a pivotal multinational Phase 3 prospective, blinded, randomized, placebo-controlled study evaluating the safety and efficacy of zalunfiban in the ambulance and other pre-hospital settings. Based in Del Mar, California, CeleCor positions itself as an innovator addressing a significant unmet medical need in early heart-attack care, aiming to reduce complications and improve outcomes for the hundreds of thousands of patients who suffer acute myocardial infarctions each year.

To learn more, visit https://www.celecor.com/
LinkedIn: https://www.linkedin.com/company/celecor

Contact:
Peter Finn, Secretary

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.